Dendreon: The Opportunity for Investors

Before you go, we thought you'd like these...
Before you go close icon

Although Dendreon's performance hasn't met lofty investor expectations, there is still real reason to be excited. In this video, Motley Fool health care analyst David Williamson discusses Dendreon's potentially revolutionary prostate cancer vaccine, Provenge, and how it can capitalize on the enormous prostate cancer market.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as Provenge became a lightning rod of debate. But where does that leave investors? David answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.


The article Dendreon: The Opportunity for Investors originally appeared on Fool.com.

Austin Smith and David Williamson have no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners